ReviewPulmonary circulation2016
Integration of complex data sources to provide biologic insight into pulmonary vascular disease (2015 Grover Conference Series).
Review in Pulmonary circulation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Variation inCirculation research · 2026Article
- Precision Medicine for Pulmonary Vascular Disease: The Future Is Now (2023 Grover Conference Series).Pulmonary circulation · 2025Article
- Evolving Schema for Employing Network Biology Approaches to Understand Pulmonary Hypertension.Advances in experimental medicine and biology · 2021Article
- Evolving systems biology approaches to understanding non-coding RNAs in pulmonary hypertension.The Journal of physiology · 2019Review
- Lack of a Tricuspid Regurgitation Doppler Signal and Pulmonary Hypertension by Invasive Measurement.Journal of the American Heart Association · 2018Article
- Article
- Translational Advances in the Field of Pulmonary Hypertension. Focusing on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension.American journal of respiratory and critical care medicine · 2017Review
- Hemodynamic evidence of vascular remodeling in combined post- and precapillary pulmonary hypertension.Pulmonary circulation · 2016Article
- Racial differences in patients referred for right heart catheterization and risk of pulmonary hypertension.Pulmonary circulationArticle
- Pulmonary hypertension in patients with chronic kidney disease: invasive hemodynamic etiology and outcomes.Pulmonary circulationArticle
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
Abstract
The application of complex data sources to pulmonary vascular diseases is an emerging and promising area of investigation. The use of -omics platforms, in silico modeling of gene networks, and linkage of large human cohorts with DNA biobanks are beginning to bear biologic insight into pulmonary hypertension. These approaches to high-throughput molecular phenotyping offer the possibility of discovering new therapeutic targets and identifying variability in response to therapy that can be leveraged to improve clinical care. Optimizing the methods for analyzing complex data sources and accruing large, well-phenotyped human cohorts linked to biologic data remain significant challenges. Here, we discuss two specific types of complex data sources-gene regulatory networks and DNA-linked electronic medical record cohorts-that illustrate the promise, challenges, and current limitations of these approaches to understanding and managing pulmonary vascular disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.